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Paracrine cyclooxygenase-2 activity 
by macrophages drives colorectal 
adenoma progression in the 
ApcMin/+ mouse model of intestinal 
tumorigenesis
Mark A. Hull1, Richard J. Cuthbert1, C. W. Stanley Ko1, Daniel J. Scott1, Elizabeth J. 
Cartwright1, Gillian Hawcroft1, Sarah L. Perry1, Nicola Ingram  1, Ian M. Carr2, Alexander F. 
Markham2, Constanze Bonifer3 & P. Louise Coletta1
Genetic deletion or pharmacological inhibition of cyclooxygenase (COX)-2 abrogates intestinal 
adenoma development at early stages of colorectal carcinogenesis. COX-2 is localised to stromal 
cells (predominantly macrophages) in human and mouse intestinal adenomas. Therefore, we tested 
the hypothesis that paracrine Cox-2-mediated signalling from macrophages drives adenoma growth 
and progression in vivo in the ApcMin/+ mouse model of intestinal tumorigenesis. Using a transgenic 
C57Bl/6 mouse model of Cox-2 over-expression driven by the chicken lysozyme locus (cLys-Cox-2), 
which directs integration site-independent, copy number-dependent transgene expression restricted 
to macrophages, we demonstrated that stromal macrophage Cox-2 in colorectal (but not small 
intestinal) adenomas from cLys-Cox-2 x ApcMin/+ mice was associated with significantly increased 
tumour size (P = 0.025) and multiplicity (P = 0.025), compared with control ApcMin/+ mice. Transgenic 
macrophage Cox-2 expression was associated with increased dysplasia, epithelial cell Cox-2 expression 
and submucosal tumour invasion, as well as increased nuclear β-catenin translocation in dysplastic 
epithelial cells. In vitro studies confirmed that paracrine macrophage Cox-2 signalling drives catenin-
related transcription in intestinal epithelial cells. Paracrine macrophage Cox-2 activity drives growth 
and progression of ApcMin/+ mouse colonic adenomas, linked to increased epithelial cell β-catenin 
dysregulation. Stromal cell (macrophage) gene regulation and signalling represent valid targets for 
chemoprevention of colorectal cancer.
There is incontrovertible genetic and pharmacological evidence from rodent models that the inducible isoform 
of prostaglandin (PG) G/H synthase (PTGS2), also known as cyclooxygenase (COX), COX-2 plays an important 
role in the early stages of intestinal tumorigenesis during adenoma (or polyp) development1–3. These pre-clinical 
studies led to investigation of the chemopreventative efficacy of selective COX-2 inhibitors in randomized, 
placebo-controlled colorectal polyp prevention trials in humans4. Predictably, both celecoxib and rofecoxib use 
were demonstrated to be associated with a significant reduction in polyp recurrence at colonoscopy, compati-
ble with a future role for selective COX-2 inhibitors in colorectal cancer (CRC) chemoprevention5–7. However, 
long-term use of coxibs caused an excess of cardiovascular thrombotic events such as myocardial infarction8, lim-
iting future use of this class of drugs for primary prevention of ‘sporadic’ CRC. Therefore, there is a requirement 
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for novel approaches, which harness the clear anti-neoplastic efficacy of COX-2 inhibition, whilst minimizing or 
avoiding systemic toxicity.
We, and others, have described that COX-2 is expressed predominantly by stromal cells in human and rodent 
intestinal adenomas9–15, rather than the dysplastic epithelial cells that eventually undergo malignant transforma-
tion. Several cell types are believed to contribute to the stromal COX-2-positive cell population in human and 
mouse intestinal adenomas including macrophages9–11, 15, (myo)fibroblasts13, 14 and endothelial cells12. In human 
tumours, the predominant COX-2-positive stromal cell population is the CD68-positive macrophage10, 11.
The predominant stromal cell localization of COX-2 in adenomas implies a role for paracrine Cox-2-mediated 
signalling during the early stages of intestinal tumorigenesis. We have demonstrated that mouse macrophage 
Cox-2 induces tumorigenic behaviour (including anchorage-independent growth and resistance to apoptosis) 
of non-transformed IEC-6 rat intestinal epithelial cells in vitro16. More recently, others have provided evidence 
that paracrine COX-2-mediated signalling from stromal fibroblasts can drive proliferation of human CRC cells 
in vitro17.
The role of paracrine COX-2-mediated signalling from stromal macrophages during the early stages of intes-
tinal tumorigenesis in vivo remains unclear. The ApcMin/+ mouse model of the early stages of intestinal tumori-
genesis remains the predominant rodent model of ‘sporadic’ colorectal adenoma development for investigating 
chemoprevention strategies18, 19. Despite the fact that the majority of adenomas are present in the small intestine 
(SI) and newer conditional mouse models, effectiveness of chemopreventive agents in the ApcMin/+ mouse model 
is highly predictive of clinical efficacy4–7. Therefore, we tested the hypothesis that increased expression of Cox-2 by 
macrophages promotes ApcMin/+ mouse intestinal tumorigenesis using a transgenic model of macrophage-specific 
Cox-2 over-expression.
Results
The cLys-Cox-2 transgenic mouse model of macrophage-specific Cox-2 expression. The chicken 
lysozyme (cLys) gene locus directs copy number-dependent, integration site-independent, macrophage-specific 
transgene expression in mice20–22. We cloned a 5.8 kb mouse genomic Cox-2 clone consisting of all 10 exons 
and a 239 bp 3′-UTR fragment into the pIIIiLysVSal30 vector (Fig. 1A)20. Functionality of the linearised 18 kb 
Sfi I-BssH II DNA fragment (including 11.5 kb of the cLys 5′-flanking region, which contains all the cis-regula-
tory elements necessary for macrophage-specific expression in mice23, but excluding the majority of the adjacent 
chicken Gas41 gene at the 3′-end of the cLys locus24), was tested in stably transfected chicken HD11 macrophages. 
Inducible mouse Cox-2 expression was demonstrated in two independent stably transfected HD11 cell clones 
(Fig. 1B,C). The 18 kb vector was then injected into the pronucleus of fertilised oocytes to generate transgenic 
founder C57Bl/6 (B6) x CBA animals, which were screened by transgene-specific cLys-Cox-2 PCR (Fig. 1D). 
Three founders termed G5, G25 and G26 were identified from 26 offspring from 5 foster mothers. Only G5 and 
G25 founders transmitted the transgene at low frequency in four (9/34) and three litters (4/27), respectively. In 
order to test transgenic expression in vivo, we measured cLys-Cox-2 transcript levels in bone marrow-derived 
macrophages (BMDMs). Unlike G5 BMDMs, unstimulated BMDMs from the G25 line exhibited cLys-Cox-2 
mRNA expression, which was induced further by (LPS) and γ-interferon (IFN), in parallel with endogenous 
mouse Cox-2 expression (Fig. 1E). Therefore, G25 mice were used exclusively for further experiments (termed 
cLys-Cox-2) and were bred to near homozygosity on the B6 background (N6 generation backcross) using an 
in-house real-time PCR method for transgene genotyping (Fig. 1F). The hemizygous transgene copy number was 
determined as 47 by direct comparison with endogenous Cox-1 genomic DNA (Fig. 1F). Whole genome DNA 
sequencing of a homozygous B6 G25 cLys-Cox-2 mouse revealed that there were 5 possible transgene insertion 
sites, four of which were flanked by major satellite (MaSat) repeats in large, transcriptionally silent intergenic 
regions25, and one of which was located in the centre of the first (360 kb) intron of the MAM domain containing 
glycosylphosphatidylinositol anchor 2 gene.
Adult B6 cLys-Cox-2 mice demonstrated no observable phenotypic differences from wild-type (WT) B6 lit-
termates and bred normally. As expected from a previous study of cLys transgene expression in mice23, transgenic 
Cox-2 protein was detected by immunohistochemistry in F4/80-positive splenocytes and hippocampal glial cells 
in cLys-Cox-2 mice (Fig. 2A–D).
Macrophage Cox-2 expression promotes ApcMin/+ mouse colonic tumorigenesis. In order to 
determine the effect of macrophage-specific Cox-2 over-expression on the early stages of intestinal tumorigenesis, 
we crossed B6 cLys-Cox-2 mice with our existing B6 ApcMin/+ mouse colony.
Cox-2 protein is known to be localized predominantly to superficial stromal cells below eroded luminal 
epithelium in ApcMin/+ mouse SI and colonic adenomas9. This Cox-2-expressing stromal cell population is het-
erogeneous but does include macrophages12, 13. Transgenic cLys-Cox-2 x ApcMin/+ mouse colorectal tumours 
demonstrated an increase in Cox-2 immunoreactivity in the stromal cell compartment below the luminal 
tumour surface compared with non-transgenic ApcMin/+ mouse colorectal tumours (P = 0.02, Mann-Whitney 
U test; Fig. 2E–G). Greater than 90% of Cox-2-positive stromal cells in transgenic tumours were F4/80-positive 
macrophages present in a similar distribution (predominantly below the luminal surface) to that observed in 
non-transgenic ApcMin/+ mouse tumours (Fig. 2H). Although we observed increased expression and function 
(measured as the tissue prostaglandin [PG] E2 content) of Cox-2 in ApcMin/+ mouse tumour tissue compared with 
adjacent non-neoplastic colonic mucosa (Fig. 2I,J), as has previously been reported26, we did not detect increased 
levels of Cox-2 mRNA or PGE2 in whole transgenic tumour samples compared with non-transgenic ApcMin/+ 
mouse tumours (Fig. 2I,J). The focal nature of Cox-2 expression in ApcMin/+ mouse tumours likely explains the 
failure to demonstrate elevated Cox-2 mRNA levels or tissue PGE2 levels in whole transgenic ApcMin/+ mouse 
tumours compared with non-transgenic tissue (Fig. 2I,J). However, we did observe a significant increase in 
Cox-2 transcript levels, as well as a non-significant increase in PGE2 content, in non-neoplastic cLys-Cox-2 x 
www.nature.com/scientificreports/
3SCIEntIfIC RePoRtS | 7:  6074 | DOI:10.1038/s41598-017-06253-5
Figure 1. Generation of cLys-Cox-2 mice. (A) Insertion of a complete mouse Cox-2 genomic DNA clone 
consisting of 10 exons (numbered solid boxes), as well as 68 bp of 5′-UTR and 239 bp 3′-UTR sequence, into 
plasmid pIIIiLysVSal30 flanked by exon 1 (5′) and exon 3 (3′) of cLys (labelled L1, L3). Linearisation of plasmid 
DNA (termed cLys-Cox-2) was carried out using Sfi I and BssH II restriction enzymes. Arrow pairs denote PCR 
primers (see Supplementary Table 1) specific for endogenous and transgenic mouse Cox-2 mRNA (mCox-2 
cDNA; red), transgenic Cox-2 mRNA only (cLys-Cox-2 cDNA; green) and transgenic DNA (cLys-Cox-2 
gDNA; blue). (B) RT-PCR for mouse Cox-2 mRNA (red primer pair), chicken lysozyme (c-Lys) mRNA and 
chicken β-actin in stably transfected HD11 cell clones, which were either unstimulated (−) or activated (+) 
with 5 μg/ml LPS for 16 hours. Two clones co-transfected with cLys-Cox-2 and pMC1 Neo both demonstrated 
inducible expression of mouse Cox-2 mRNA unlike control cells transfected with pMC1 Neo alone. By contrast, 
all cell clones exhibited inducible endogenous c-Lys and constitutive β-actin expression. H20 denotes PCR 
reactions with no cDNA template added. (C) Immunofluorescence for mCox-2 protein on unstimulated and 
LPS-stimulated HD11 clone 2 cells. Left-hand panels show DAPI-stained nuclei only with corresponding 
FITC-labelling of mCox-2 in 5-10% of LPS-stimulated cells (arrows). Cox-2 protein was not detected in 
LPS-stimulated pMC1 Neo-transfected cells using polyclonal anti-Cox-2 antibody (Cayman 160126; data not 
shown). (D) Identification of transgenic founder animals by PCR genotyping of tail-tip DNA using cLys-Cox-2 
gDNA primers (see Supplementary Table 1). (E) cLys-Cox-2 expression in vivo. Transcript analysis in BMDMs 
from G25 transgenic mice and wild-type (WT) controls for transgenic and endogenous Cox-2 and Gapdh. 
H20 denotes PCR reactions with no cDNA template added. (F) Real-time PCR genotyping for the cLys-Cox-2 
transgene in the G25 line. The transgene copy number was determined as the ratio of cLys-Cox-2/Cox-1 DNA 
divided by two and then subtracted by two (the endogenous Cox-2 gene copies). Bars represent the mean and 
standard error of the mean (SEM) values from tail-tip DNA from 30 (homozygous) and 50 (heterozygous) mice. 
Figure 1B,D and E are cropped gel images. No bands have been omitted by editing.
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Figure 2. Cox-2 expression in cLys-Cox-2 mouse tissues. Cox-2 immunohistochemistry on (A) spleen 
from a cLys-Cox-2 mouse (day 100) showing Cox-2 protein localisation to transgenic splenocytes unlike 
(B) spleen from an aged-matched WT mouse. (C) Dual immunofluorescence for Cox-2 (green) and F4/80 
(blue) demonstrating localisation of Cox-2 to splenic macrophages (arrows show examples). Cox-2-positive 
macrophages represent a subset of the total F4/80-positive splenocyte population. (D) Localisation of Cox-2 
protein to hippocampal cells in cLys-Cox-2 mouse brain. No Cox-2 protein was detectable in equivalent sections 
from WT brain (data not shown). Cox-2 protein localization in transgenic cLys-Cox-2 x ApcMin/+ mouse colonic 
tumours and non-transgenic ApcMin/+ mouse colonic adenomas. (E) Strong Cox-2 staining (Cox-2 score 
4) in superficial stromal cells (arrows) below the luminal surface of a cLys-Cox-2 x ApcMin/+ mouse colonic 
tumour. Size bar = 50 μm. (F) Patchy Cox-2-positive superficial stromal cells (arrows) in a non-transgenic 
ApcMin/+ mouse adenoma (Cox-2 score 1). Size bar = 50 μm. (G) Individual stromal Cox-2 scores of transgenic 
(n = 10) and non-transgenic (n = 8) ApcMin/+ mouse tumours. *P = 0.02, Mann-Whitney U test. (H) Dual 
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ApcMin/+ mouse colonic mucosa compared with non-transgenic ApcMin/+ mouse colonic mucosa (Fig. 2I,J and 
Supplementary Information).
Intestinal phenotype analysis at 100 days of age demonstrated that cLys-Cox-2 x ApcMin/+ mice developed a 
significantly larger number of colonic tumours than non-transgenic ApcMin/+ animals (P = 0.03, Mann-Whitney 
U Test; Fig. 3A). Colonic tumours from cLys-Cox-2 x ApcMin/+ mice were also larger than in non-transgenic coun-
terparts (P = 0.025, one-way ANOVA) although this was not evident in the largest colonic tumours, perhaps due 
to the small number of tumours greater than 6 mm in diameter (Fig. 3A). By contrast, there was no significant 
difference in SI tumour multiplicity or size in cLys-Cox-2 x ApcMin/+ mice compared with non-transgenic controls 
(Fig. 3B). There were no gender-specific differences in tumour size or multiplicity in either cLys-Cox-2 x ApcMin/+ 
mice or non-transgenic controls (data not shown). Consistent with accelerated colorectal tumorigenesis in trans-
genic animals, 5 of 10 (50%) colonic tumours from cLys-Cox-2 x ApcMin/+ mice were adenomas with severe epi-
thelial dysplasia (Fig. 4A,B), whereas 8 colonic adenomas examined from non-transgenic ApcMin/+ mice contained 
epithelial cells with only low or moderate grade dysplasia, but no severe dysplasia (P = 0.04, Fisher’s Exact Test). 
In addition, 3 colonic tumours in cLys-Cox-2 x ApcMin/+ mice demonstrated evidence of localized deep invasion of 
the muscularis mucosae by nests of epithelial cells consistent with tumour progression towards adenocarcinoma 
(Fig. 4C,D).
Six cLys-Cox-2 x ApcMin/+ mouse tumours contained patchy epithelial cells that expressed Cox-2 protein 
(Fig. 4E,F), in contrast to non-transgenic ApcMin/+ mouse adenomas, which consisted only of Cox-2-negative epi-
thelium, a finding similar to previous immunohistochemical studies of non-transgenic ApcMin/+ mouse tumours 
using the same rabbit polyclonal anti-Cox-2 antibody from Cayman Chemical Co.9. The pattern of Cox-2 immu-
noreactivity was similar in adjacent tissue sections stained with a different anti-Cox-2 antibody from Santa Cruz 
Biotechnology Inc. (Fig. 4G). Epithelial cell Cox-2 protein expression was prominent in nests of cells at the base of 
the tumour and within cells invading neighbouring muscularis mucosae (Fig. 4F,G). Epithelial cell Cox-2 expres-
sion was driven from the endogenous Cox-2 gene rather than epithelial cell transgene expression based on the 
absence of consistent co-localization of lysozyme and Cox-2 proteins in epithelial cells (Fig. 4H–J) and our ina-
bility to detect transgenic transcripts in micro-dissected epithelium from transgenic adenomas (data not shown).
By contrast, there was no increase in stromal Cox-2 immunoreactivity in transgenic cLys-Cox-2 x ApcMin/+ 
mouse tumours anywhere in the SI compared with non-transgenic ApcMin/+ mouse SI tumours (median 
[inter-quartile range] non-transgenic Cox-2 score 21–3 for n = 27 versus transgenic Cox-2 score 11–3 for n = 25; 
P = 0.29, Mann-Whitney U test). Subgroup analysis of adenomas restricted to proximal, middle or distal thirds 
of the SI similarly demonstrated no significant difference in stromal Cox-2 scores between transgenic and 
non-transgenic ApcMin/+ mouse adenomas (data not shown). There was also no evidence of adenomatous epithe-
lial cell Cox-2 localisation in transgenic cLys-Cox-2 x ApcMin/+ mouse SI adenomas, unlike counterpart colonic 
tumours.
Increased macrophage Cox-2 in cLys-Cox-2 x ApcMin/+ mouse colonic adenomas drives nuclear 
β-catenin localization via paracrine macrophage-epithelial cell signalling. We have previously 
reported that the presence of stromal Cox-2-positive macrophages in human colorectal adenomas is associated 
with an increased microvessel density (MVD) indicative of increased angiogenesis, which could account for 
accelerated intestinal tumorigenesis in cLys-Cox-2 x ApcMin/+ mice11, 27. Therefore, we measured the CD31-positive 
MVD of transgenic and non-transgenic ApcMin/+ mouse colonic adenomas (Fig. 5A,B). Increased MVD was 
observed in transgenic colonic tumours but the difference from non-transgenic tumours did not reach statistical 
significance (Fig. 5C).
Alternatively, direct paracrine signalling between macrophages and neighbouring epithelial cells could explain 
the increased colonic tumour multiplicity and progression observed in transgenic cLys-Cox-2 x ApcMin/+ mice. 
Castellone et al.28 have reported that PGE2 can stimulate β-catenin-related transcription in human CRC cells 
lacking Adenomatous Polyposis Coli function. It is also established that dysplastic epithelial cells in ApcMin/+ mouse 
adenomas exhibit increased levels and nuclear localization of β-catenin, following loss of the second Apc allele29. 
Therefore, we compared localization of β-catenin protein in transgenic and non-transgenic colonic tumours 
(Fig. 5D–F). β-catenin immunoreactivity was increased and localized to the nucleus in epithelial cells of ApcMin/+ 
mouse colorectal tumours compared with neighbouring non-neoplastic mucosa (Fig. 5D). Moreover, nuclear 
localization of β-catenin was increased significantly (P = 0.03) in transgenic cLys-Cox-2 x ApcMin/+ mouse tumours 
compared with non-transgenic ApcMin/+ mouse tumours (Fig. 5F) indicative of increased β-catenin-related tran-
scription in transgenic tumours.
We have previously described Cox-2-mediated pro-tumorigenic macrophage-intestinal epithelial cell sig-
nalling in a co-culture model using RAW264.7 mouse macrophages and rat IEC-6 cells16. Therefore, we tested 
immunofluorescence for Cox-2 (green) and the macrophage marker F4/80 (blue) in a cLys-Cox-2 x ApcMin/+ 
mouse colonic tumour. Greater than 90% of Cox-2-positive stromal cells exhibit F4/80 positivity (closed 
arrows) but are only a subset of the total intra-tumoral F4/80 macrophage population (asterisks) in transgenic 
colonic tumours. (I) Cox-2 mRNA levels in colonic tumour tissue (shaded columns) and adjacent non-
neoplastic colonic mucosa (open columns) from non-transgenic (WT) and transgenic (cLys-Cox-2) animals. 
Columns and bars represent the mean and SEM from three separate animals. *P = 0.01 for the comparison with 
non-transgenic ApcMin/+ mouse colonic mucosa (Student’s t-test). (J) Tissue PGE2 levels in colonic tumour tissue 
(shaded columns) and adjacent non-neoplastic colonic mucosa (open columns) from non-transgenic (WT) and 
transgenic (cLys-Cox-2) animals. Columns and bars represent the mean and SEM from ten separate animals. 
*P = 0.12 for the comparison with non-transgenic ApcMin/+ mouse colonic mucosa (Student’s t-test).
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whether macrophage Cox-2 activity increased β-catenin levels and β-catenin-related transcription in epithelial 
cells, in this in vitro model. Cells cultured in the presence of Cox-2-positive activated macrophage-conditioned 
medium contained higher levels of β-catenin protein (particularly the smaller 90 kDa product) compared with 
control cells (Fig. 5G). Importantly, if the activated macrophage-conditioned medium was produced in the pres-
ence of the selective Cox-2 inhibitor SC-236, there was less induction of β-catenin in epithelial cells (Fig. 5G). 
However, addition of SC-236 after the medium had been conditioned did not have any effect on β-catenin 
levels, thereby ruling out a direct effect of SC-236 on epithelial cells (Fig. 5G). We also observed increased 
β-catenin-related transcriptional activity (measured by the β-catenin/T cell factor-reporter TOPflash) in epi-
thelial cells cultured in the presence of activated macrophage-conditioned medium, which is consistent with the 
increase in β-catenin protein levels detected by Western blot analysis.
Overall, we have demonstrated that nuclear localization of β-catenin (a tissue biomarker of β-catenin-related 
transcription) is increased in transgenic Cox-2-over-expressing cLys-Cox-2 x ApcMin/+ mouse tumours and that 
paracrine macrophage Cox-2 activity directs increased β-catenin levels and transcriptional activity in epithelial 
cells.
Figure 3. Colonic tumour number and size are increased in cLys-Cox-2 x ApcMin/+ mice. Colonic (A), but not 
SI (B), tumour multiplicity and size are increased in cLys-Cox-2 x ApcMin/+ mice compared with non-transgenic 
controls. Post-mortem intestinal phenotype analysis was performed at 100-110 days of age by one observer 
blinded to genotype. Dots represent individual tumour numbers for 11 non-transgenic and 12 transgenic 
animals. Lines represent median values. Columns and bars represent the mean and SEM number of tumours 
in different size categories from non-transgenic (empty) and transgenic (shaded) ApcMin/+ mice. *P ≤ 0.03. 
**P = 0.025.
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Figure 4. Histological features of cLys-Cox-2 x ApcMin/+ mouse colonic tumours stained with H&E. (A) cLys-
Cox-2 x ApcMin/+ mouse colonic tumour demonstrating disorganised clusters of severely dysplastic epithelial 
cells. Size bar = 50 μm. (B) Non-transgenic ApcMin/+ mouse colonic tumour demonstrating typical features 
of low-grade dysplasia. Size bar = 50 μm. (C and D) Separate cLys-Cox-2 x ApcMin/+ mouse colonic tumours 
demonstrating invasion of neighbouring submucosa by dysplastic epithelial cells (arrows). (E) Patchy dysplastic 
epithelial cells staining for Cox-2 (arrows) in a cLys-Cox-2 x ApcMin/+ mouse colonic tumour (stromal Cox-2 
score 4). Size bar = 50 μm. (F) Epithelial cell Cox-2 protein localization in cells at the base of a cLys-Cox-2 x 
ApcMin/+ mouse colonic tumour (arrows). Size bar = 50 μm. (G) Adjacent sections of a cLys-Cox-2 x ApcMin/+ 
mouse colonic tumour stained with either the Cayman (Cay) or Santa Cruz (SC) anti-Cox-2 antibody. Note 
prominent patchy epithelial cell staining (arrowheads) in addition to stromal cell staining (asterisk) in the same 
distribution in both panels. In general, adenomatous epithelial cell staining with the Santa Cruz antibody was 
consistently more widespread than with the Cayman antibody. Size bars = 50 μm. Immunohistochemistry for 
Cox-2 (using the Cayman antibody [H]) and lysozyme (J) on adjacent sections of a cLys-Cox-2 x ApcMin/+ mouse 
colonic tumour. Size bars = 50 μm. There was no correlation between Cox-2 and lysozyme immunoreactivity in 
individual adenomatous epithelial cells.
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Figure 5. Transgenic cLys-Cox-2 x ApcMin/+ mouse colonic tumours have increased tumour-associated 
angiogenesis and nuclear β-catenin localisation in dysplastic epithelial cells. (A) Immunohistochemistry for 
mouse CD31 demonstrating capillary microvessels in a non-transgenic ApcMin/+ mouse colonic tumour. Size 
bar = 50 μm. (B) CD31-positive endothelial cells in microvessels in a transgenic cLys-Cox-2 x ApcMin/+ mouse 
colonic tumour. Size bar = 50 μm. (C) Microvessel density (number of CD31-positive foci per ‘hotspot’ 100 
x microscopic field) in ApcMin/+ mouse colonic tumours. Bars represent the mean and SEM of the MVD for 
non-transgenic ApcMin/+ mouse tumours (n = 8) and transgenic cLys-Cox-2 x ApcMin/+ mouse tumours (n = 6). 
*P = 0.25; Student’s t test). (D) Immunohistochemistry for β-catenin on a transgenic cLys-Cox-2 x ApcMin/+ 
mouse colonic tumour demonstrating strong nuclear and cytoplasmic β-catenin immunoreactivity (score 
4) in dysplastic epithelial cells (black arrows) compared with the membranous distribution of β-catenin and 
absence of nuclear staining in neighbouring non-neoplastic epithelium (white arrow). Size bar = 50 μm. (E) 
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Discussion
Our transgenic, macrophage-specific Cox-2 over-expression model provides the first direct evidence that 
increased stromal macrophage Cox-2 can drive ApcMin/+ mouse tumour progression in the colorectum, analo-
gous to human colorectal polyp growth and malignant progression. This confirms stromal macrophage Cox-2 as 
a tumour-specific target for secondary chemoprevention of CRC. Previously, ‘knockout’ studies have implicated a 
role for Cox-2 in the early stages of intestinal tumorigenesis1, 2. Despite one of the studies confirming that expres-
sion of Cox-2 in mouse mutant Apc intestinal adenomas was restricted to stromal rather than epithelial cells1, 
these reports stopped short of providing proof that stromal cell Cox-2 up-regulation could drive rodent intestinal 
tumorigenesis. Our data now provide a strong rationale for targeting COX-2 expression in tumour-associated 
macrophages as a CRC chemoprevention strategy that is unlikely to share the cardiovascular toxicity associ-
ated with systemic pharmacological COX-2 inhibition8. For example, tumour-associated macrophages are now 
recognised as a target for anti-cancer nanotherapy30. Stromal macrophages also secrete other pro-tumorigenic 
mediators including WNTs and multiple chemokines/cytokines31, 32. However, it should be noted that other cell 
types contribute to stromal COX-2 expression in intestinal adenomas, at least in the mouse, namely fibroblasts 
and endothelial cells12.
Macrophage Cox-2-dependent tumour growth and progression in ApcMin/+ mice was restricted to the colon 
and was not observed in the SI. This may be due to the larger stromal inflammatory infiltrate observed in large 
colonic tumours33, thus driving an increased transgenic Cox-2-dependent paracrine signal. Our data are compat-
ible with those of Cherukuri and colleagues, who reported that myeloid cell-specific Cox-2 deletion in a Cox-2fl°x/
fl°x x LysMCre/+ mouse model did not alter SI tumour number or size34. In that study, the small number of colonic 
tumours precluded specific analysis of the effect of myeloid cell-specific Cox-2 deletion in the colon34.
Pharmacological inhibition of stromal macrophage COX-2 expression is dependent on understanding the 
mechanistic basis of macrophage infiltration and COX-2 up-regulation in intestinal adenomas. COX-2-positive 
tumour-associated macrophages in human (and mouse) intestinal adenomas exhibit a phenotype that is not 
entirely compatible with either classical (M1) macrophage activation or alternatively activated macrophages 
(M2). For example, Cox-2-positive tumour-associated macrophages in ApcMin/+ mouse adenomas do not express 
inducible nitric oxide synthase (Nos) 235, which would be expected in classically activated M1 macrophages36, 37. 
Instead, F4/80-positive macrophages in ApcMin/+ mouse tumours express arginase I, a recognised M2 marker15. 
Moreover, COX-2-positive macrophages in human colorectal adenomas contain activated nuclear factor κB38, 
which has recently been implicated in maintenance of an M2 phenotype of tumour-associated macrophages39. 
Mosser and Edwards36 have proposed a classification of macrophage populations based on different activities 
(host defence, wound healing or immune regulation), which can co-exist such that macrophages can exhibit 
features at either end of the macrophage phenotype spectrum with inherent plasticity. We hypothesize that 
Cox-2-positive, Nos2-negative, NFκB-positive macrophages in intestinal adenomas likely exhibit a ‘regulatory’ 
phenotype. Interestingly, pharmacological Cox-2 inhibition in the ApcMin/+ mouse has been reported to switch 
tumour-associated macrophages from an M2 to M1 phenotype33.
The micro-environmental stimulus for macrophage Cox-2 up-regulation remains unknown. Predominant 
localization of Cox-2-positive cells below eroded surface epithelium in intestinal adenomas suggests that exposure 
to luminal antigen may explain Cox-2 up-regulation in macrophages40. However, we have previously been unable 
to demonstrate an intestinal permeability defect in ApcMin/+ mouse intestine24. Intracellular CRC-associated E. 
coli has been demonstrated to drive persistent COX-2 expression in human THP-1 macrophages41. Alternative 
suggested stimulatory signals include mucins produced by neighbouring epithelial cells42, secondary bile acids43 
and direct epithelial-to-stromal cytokine/chemokine signalling eg. by monocyte chemoattractant protein 144. 
Interplay with other immune cell types, including regulatory T cells, is also likely to modulate the macrophage 
phenotype32, 45, although this has not been studied in detail in colorectal adenomas, as opposed to CRCs.
Although Cox-2 expression is restricted to the stromal cell compartment in ApcMin/+ mouse intestinal 
tumours9, 12, 13, 15 and is predominantly localised to stromal cells in human colorectal adenomas [10–11,14, 
46–47), COX-2 is strongly expressed by malignant epithelial cells in CRCs suggesting a stage-specific switch to 
epithelial cell COX-2 expression11, 46. This is the first report of epithelial cell Cox-2 localization in ApcMin/+ mouse 
colonic adenomas. We propose that epithelial cell Cox-2-expression in our cLys-Cox-2 x ApcMin/+ mouse model 
is analogous to the switch to epithelial cell COX-2 protein expression in human colorectal adenomas that exhibit 
‘advanced’ features (increased size, high-grade dysplasia, villous architecture) associated with tumour progression 
to cancer11, 47, 48. Consistent with stage-specific Cox-2 expression during colorectal carcinogenesis, Al-Salihi and 
Immunohistochemistry for β-catenin on a non-transgenic ApcMin/+ mouse colonic tumour demonstrating 
patchy, weak nuclear β-catenin staining (score 1) in dysplastic epithelial cells. Size bar = 50 μm. (F) Nuclear 
β-catenin scores of non-transgenic ApcMin/+ (n = 7) and transgenic cLys-Cox-2 x ApcMin/+ (n = 9) mouse colonic 
tumours. P = 0.03, Mann-Whitney U test). (G) Western blot analysis of β-catenin protein content of rat IEC-6 
epithelial cells. Cells were cultured for 12 weeks in the presence of control medium alone (con), non-activated 
macrophage-conditioned medium (NMCM), activated macrophage-conditioned medium (AMCM), activated 
macrophage-conditioned medium (AMCM) produced in the presence of 1 μM SC-236 (SC-AMCM) or 
activated macrophage-conditioned medium (AMCM), to which 1 μM SC-236 was added after production 
(AMCM + SC). The β-catenin doublet was 90-92 kDa in size. β-actin (42 kDa) was used as a loading control. 
The images of the blots are cropped but no bands have been omitted by editing. (H) TOPflash activity in control 
IEC-6 cells (con) or IEC-6 cells cultured in the presence of AMCM for 12 weeks. Data are TOPflash firefly 
luciferase values normalised to Renilla luciferase activity. No FOPflash luciferase activity was detectable (data 
not shown). Columns and bars represent the mean and SEM of triplicate values.
www.nature.com/scientificreports/
1 0SCIEntIfIC RePoRtS | 7: 6074  | DOI:10.1038/s41598-017-06253-5
colleagues have previously reported that intestinal epithelial cell Cox-2 drives progression, but not initiation, of 
azoxymethane-induced colonic tumours49. Pro-tumorigenic activity of COX-2 in different tumour cell compart-
ments suggests that COX-2 likely has autocrine/paracrine effects independent of cell-specific expression.
Severe dysplasia and local invasion of intestinal adenomas in the ApcMin/+ mouse model is rarely seen18. The 
cLys-Cox-2 x ApcMin/+ mouse may find use as a model of carcinoma-in-situ, also known as malignant colorectal 
polyp, which has become a clinically important lesion, especially with the advent of colonoscopic screening.
We report that tumour-associated macrophage Cox-2 over-expression was associated with increased nuclear 
β-catenin localization in ApcMin/+ mouse colonic adenomas and that paracrine Cox-2-dependent signalling from 
macrophages increases catenin-related transcription in intestinal epithelial cells. Exogenous PGE2 has been 
demonstrated to activate Wnt signalling in human CRC cells in vitro via EP2 receptor-dependent activation of 
PI3K/AKT and direct inhibition of glycogen synthase kinase 3β28. Future work will determine whether PGE2-EP2 
receptor signalling (or that of other EP receptor family members, particularly EP4) in epithelial cells, as well 
as the stromal cell compartment15, explains increased colonic tumorigenesis in cLys-Cox-2 x ApcMin/+ mice. In 
another in vitro model, Kaler and colleagues have reported that human THP-1 monocyte-conditioned medium 
induces catenin-related transcription in HCT116 human CRC cells50. It has been proposed that a further increase 
in β-catenin levels and nuclear translocation of β-catenin, in addition to underlying Wnt signalling dysregula-
tion secondary to APC loss of function, driven by stromal cell signalling promotes malignant tumour growth 
and metastatic behaviour51. However, there is not a precise correlation between tumour phenotype and nuclear 
β-catenin and further work is necessary to delineate paracrine effectors of WNT signal dysregulation in intestinal 
epithelial cells52. Our data suggest that a paracrine COX-2-mediated signal drives tumour progression in cells 
that have already lost Apc function at earlier stages of colorectal carcinogenesis relevant to primary and secondary 
prevention.
Predominant stromal cell COX-2 localisation during the pre-malignant phase followed by neoplastic epithe-
lial cell COX-2 expression during malignant progression has been observed in other parts of the gastrointestinal 
tract, in which chronic inflammation predisposes to carcinogenesis, such as reflux oesophagitis/Barrett’s oesoph-
agus53 and Helicobacter pylori-associated chronic gastritis54. Therefore, our transgenic cLys-Cox-2 mouse model of 
macrophage Cox-2 expression may be a useful experimental tool for investigation of tumour progression at early 
stages of carcinogenesis in other parts of the gastrointestinal tract.
Materials and Methods
Animals. All experiments were were undertaken with UK Home Office (HO) approval, in accordance with 
HO guidelines and Institutional policies. Animals were housed in a specific pathogen-free environment.
Generation of cLys-Cox-2 transgenic mice. A 5728 bp product consisting of the complete open reading frame of 
mouse Cox-2 with 68 bp of 5′-UTR and 239 bp of 3′-UTR was generated by PCR (Extensor Long PCR enzyme 
mix [ABgene®, Thermo Fisher Scientific, Epsom, UK]) from mouse genomic DNA using primers incorporating 
Sal I (sense) and Mlu I (antisense) restriction sites (see Table 1). The PCR product was cloned into pGEM-T Easy 
for confirmatory sequencing.
The vector carrying the cLys locus was pIIIiLysVSal3020, which contains the complete 21 kb locus except that 
there is a 700 bp deletion in intron 2 and replacement of the cLys translation start site by a Sal I restriction site. 
The genomic mouse Cox-2 clone was ligated with Sal I/Mlu I-digested pIIIiLysVSal30 followed by transformation 
of ultra-competent E. coli (XL-10 Gold, Agilent Technologies, Stockport, UK). The resulting 26 kb cLys-Cox-2 
construct was linearised with Sfi I and BssH I giving an 18 kb species minus 5 kb of 3′ flanking sequence, which 
contains the majority of the adjacent chicken Gas41 gene and 2.1 kb of backbone vector sequence.
The 18 kb vector was then used for pronuclear injection of fertilised oocytes to generate transgenic founder B6 
x CBA animals, which were then screened by transgene-specific (cLys-Cox-2) PCR.
cLys-Cox-2 copy number in B6 cLys-Cox-2 transgenic mice was determined by comparison with the corre-
sponding endogenous Cox-1 gene copy number.
Genomic DNA was extracted from ground tail tissue by adding 0.5 ml TKM buffer (10 mM Tris-HCl pH 7.6, 
10 mM KCl, 2 mM EDTA, 4 mM MgCl2) including 1.25% (v/v) NP-40, centrifugation at 3000 g for 5 minutes, 
followed by re-suspension in 0.4 ml TKM buffer plus 0.75% (v/v) SDS and 20% (v/v) Chelex resin (Bio-Rad 
Laboratories Ltd., Hemel Hempstead, UK). After incubation at 55 °C for 30 minutes, 0.2 ml of 6 M NaCl was 
Primer pair Sense (5′-3′) Antisense (5′-3′) size (bp)
mCox-2 gDNAa dACGCGTCGACGAATCTCAGCACTGCATCCTGCC dCGACGCGTCTTCTGTTATGGAAGATGTTACATG 5728
mCox-2 cDNA dTCAAAAGAAGTGCTGGAAAAGGTT dTCTACCTGAGTATCTTTGACTGTG 296
cLysozyme cDNA dGATCGTCAGCGATGGAAACGGC dCTCACAGCCGGCAGCCTCTGAT 101
cβ-actin dAGATGACACAGATCATGTTT dTCCACATCACACTTCATGAT 511
cLys-Cox-2 gDNA dCCACCTGCCACTGAATGGCT dCGGAAGAGCATCGCAGAGGTG 602
cLys-Cox-2 cDNA dTCAAAAGGCGTTCAACTGAGC dCTCACAGCCGGCAGCCTCTGAT 351
real-time mCox-1 gDNA dTGGAGATGACGGGTCTGTCTTAG dACTTGTCTTCATCAGGAACAAAACTC —
real-time mCox-2 gDNA dGAATTTTTTTTCATGTAACATCTTCCATAA dGGACAAACACCGGAGGAATCT —
Table 1. PCR primer sequences and expected PCR product size. aSense and antisense primers contain Sal I and 
Mlu I recognition sites respectively (italicized). m, mouse. c, chicken.
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added and the solution was centrifuged at 16000 g for 10 minutes. Propan-2-ol (0.35 ml) was added to 0.5 ml of 
the resulting supernatant and left at −20 °C overnight. DNA was pelleted and washed with 70% (v/v) ethanol by 
centrifugation at 16000 g for 10 minutes and then re-suspended in 25 μl TE buffer at 50°C for 60 minutes.
SYBR-Green™ real-time PCR using Cox-2 (1 μmol/μl) and Cox-1 (500 nmol/μl) primers (see Table 1) was 
performed as described55 using an ABI7700 machine (Thermo Fisher Scientific).
A whole genome library with a typical insert size of approximately 200 bp was generated using NEBNext® 
Ultra™ DNA library prep (New England Biolabs, Inc., Ipswich, MA). One lane of 100 bp paired-end reads data 
was generated from the library using a HiSeq 2500 sequencer (Illumina UK, Cambridge, UK) in high volume 
mode. The sequence data was aligned to sequences consisting of the entire mouse genome (GRCm38) and the 
chicken lysozyme gene using the BWA aligner56. The aligned data were then scanned for read pairs, in which one 
read was found to align predominantly to the mouse genome and its read mate was found to align primarily to 
chicken lysozyme sequence. From these reads, a contig of those mapping to the mouse genome was created and 
possible integration sites for the transgene were found by identifying sequences in the mouse genome that were 
homologous to the contig consensus sequence.
ApcMin/+ mouse model of familial adenomatous polyposis. B6 ApcMin/+ mice from our established colony were 
bred with B6 cLys-Cox-2 mice in order to produce transgenic homozygous cLys-Cox-2 x ApcMin/+ mice and 
non-transgenic ApcMin/+ control animals. Genotyping for the ApcMin allele was performed as described35. Animals 
were provided with AIN-76 chow (Thermo Fisher Scientific) and drinking water ad libitum. ApcMin/+ mice were 
sacrificed by cervical dislocation between 100–110 days of age.
Intestinal phenotype analysis. The number and size of intestinal tumours were measured in whole spec-
imens blinded to genotype using a dissecting microscope as described previously35. Proximal, middle and distal 
thirds of the SI and colon were ‘swiss-rolled’ and fixed in 4% paraformaldehyde (w/v) before embedding in par-
affin. Separate tumour and non-neoplastic mucosal samples were OCT-embedded and snap-frozen in liquid N2. 
Samples of spleen, liver, kidney, brain and lung were also collected at the same time.
Immunohistochemistry and immunofluorescence. Routine histological analysis was performed on 
4 μm paraformaldehyde-fixed, paraffin-embedded sections stained with haematoxylin and eosin (H&E).
Immunohistochemistry for Cox-2 using affinity-purified rabbit anti-serum (160106, Cayman Chemical Co., 
Ann Arbor, MI) was performed as described9. Cox-2 immunohistochemistry was also performed using a goat 
polyclonal anti-Cox-2 antibody (sc-1745, Santa Cruz Biotechnology, Inc., Dallas, TX), which was either indirectly 
labelled with biotinylated anti-goat immunoglobulin, for visualisation with a biotinylated rabbit anti-rat second-
ary antibody (DAKO UK Ltd., Ely, UK) and Vectorstain® ABC (Vector Laboratories, Inc.), or directly conjugated 
with AlexaFluor® 488 (Thermo Fisher Scientific)57. Tumour stromal cell Cox-2 immunoreactivity was scored 
0–4 based on intensity and distribution in superficial areas of tumours below the luminal surface (0; no staining: 
1; weak, patchy staining: 2; moderate staining with some continuity: 3, intense, continuous staining in a distinct 
area: 4; intense staining throughout the tumour).
Rat monoclonal F4/80 antibody (clone Cl:A3-1; Serotec, Thermo Fisher Scientific) was visualised using a 
biotinylated rabbit anti-rat-Ig antibody (Santa Cruz Biotechnology, Inc.) and avidin-AMCA (Vector Laboratories, 
Inc., Burlingame, CA).
MEC 13.3 rat anti-mouse CD31 antibody (BD Biosciences, Oxford, UK) was used to visualise capillary 
microvessels for determination of tumour MVD blinded to genotype, as described by our Group previously58, 
using antigen retrieval with 20 μg/ml proteinase K for 25 minutes at 37 °C. Immunoreactivity was visualised with 
a biotinylated rabbit anti-rat secondary antibody (DAKO UK Ltd.) and Vectorstain® ABC (Vector Laboratories, 
Inc.), using 3,3′-diaminobenzidine as the substrate.
Immunohistochemistry for β-catenin was performed on fixed tissue sections, which had undergone 800 Watt 
microwave antigen retrieval for 10 minutes in 10 mM citrate buffer pH 6.0, using rabbit polyclonal anti-human 
β-catenin antibody (Cell Signaling Technology, Inc., Danvers, MA). Visualisation was achieved using a rabbit 
EnVision™ kit (DAKO UK Ltd.). The number and intensity of positively-stained epithelial cell nuclei in colorectal 
tumours was counted semi-quantitatively on a scale of 1–4 in a blinded manner.
Real-time RT-PCR. Total RNA extraction, reverse transcription and real-time PCR was performed as 
described59 using the ΔCt method, with the mean of three ‘housekeeping’ genes (PsmB6, Gapdh, β-actin) as the 
comparator Ct value. Primers for endogenous mouse Cox-2 are detailed in Table 1.
Measurement of mucosal and cell-conditioned medium PGE2 levels. Intestinal tissue was 
homogenised in 1 ml ice-cold Lysis Reagent 1 (Biotrak prostaglandin (PG) E2 enzyme-linked immunoassay, GE 
Healthcare, Amersham, UK) in the presence of 10 µM indomethacin (Sigma-Aldrich Co. Ltd., Dorset, UK,) using 
a 7 ml glass Dounce Homogeniser. Homogenates were centrifuged at 580 g for 5 minutes at 4 °C and the super-
natant centrifuged again at 100,000 g for 1 hour at 4 °C. The resulting solution was added to an equal volume of 
Lysis Reagent 2 and stored at −20 °C prior to immunoassay and total protein measurement (DC Protein Assay 
[Bio-Rad Laboratories Ltd.]). PGE2 levels are quoted as pg PGE2/mg total protein.
Chicken HD11 and mouse bone marrow-derived macrophage experiments. HD11 
pro-macrophage cells60 were cultured in Iscove’s-modified Dulbecco’s Medium with Glutamax™ supplemented 
with 8% (v/v) foetal calf serum, 2% (v/v) chicken serum, 100 U/ml penicillin, 100 U/ml streptomycin and 0.15 μM 
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monothioglycerol (all Life Technologies, Thermo Fisher Scientific). Stable transfection with cLys-Cox-2 and 
pMC1 Neo was performed by the calcium phosphate method in G418-containing selection medium (700 μg/ml).
Mouse bone marrow-derived macrophages were obtained and cultured as described35.
Macrophages were activated with either 5 μg/ml LPS alone for HD11 cells or 1 μg/ml LPS, in combination with 
100 U/ml γ-IFN for BMDMs, for 16 hours.
Macrophage-epithelial cell indirect co-culture. Rat IEC-6 intestinal epithelial cells were cultured in 
medium conditioned by γIFN/LPS-activated or non-activated RAW264.7 mouse macrophages, which had been 
cultured in the absence or presence of the selective COX-2 inhibitor SC-236, as described16.
Western blot analysis. Western blot analysis was performed as described61 using a 1:5000 dilution of goat 
polyclonal anti-Cox-2 antibody (Santa Cruz sc-1745) and a 1:20000 dilution of mouse monoclonal anti-β-actin 
antibody (clone 6F9; Sigma-Aldrich Co. Ltd.) in Tris-buffered saline with 0.1% (v/v) Tween-20 and 1% (w/v) 
dried skimmed milk. Secondary antibodies were either peroxidase-conjugated (DAKO) for chemilumines-
cence with ECL Western Blot Substrate (Pierce™, Thermo Fisher Scientific) or AlexaFluor 680- (Thermo Fisher 
Scientific) and IRDye800-conjugated (Rockland Immunochemicals, Limerick, PA) for measurement of Cox-2 
protein levels, which were normalised to the β-actin protein level by near-infrared analysis using an Odyssey® 
detection system (LI-COR Biotechnology UK Ltd., Cambridge, UK). Western blot analysis of rat IEC-6 β-catenin 
levels was performed using a 1:5000 dilution of mouse anti-chicken β-catenin antibody (6F9, Sigma-Aldrich) as 
described62.
Transient transfection of intestinal epithelial cells and dual luciferase reporter 
assay. Transfection of the β-catenin/T cell factor-reporter construct TOPflash and control construct 
FOPflash, followed by dual luciferase assay of reporter activity controlled for transfection efficiency, was per-
formed as described61.
Statistical analysis. All analyses were performed using SPSS version 20 and statistical significance was 
assigned if P < 0.05.
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